Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CHINA OILFIELD
02883
5
YANCHANG PETRO
00346
HK Stock MarketDetailed Quotes
CSPC PHARMA (01093)
- 9.030
- -0.320-3.42%
Trading Apr 17 10:38 CST
104.05BMarket Cap24.21P/E (TTM)
9.300High9.000Low28.09MVolume9.250Open9.350Prev Close255.27MTurnover0.24%Turnover Ratio24.21P/E (Static)11.52BShares11.49052wk High2.83P/B104.05BFloat Cap5.10052wk Low0.24Dividend TTM11.52BShs Float12.459Historical High0.262Dividend LFY3.21%Range %-2.039Historical Low9.088Avg Price2000Lot Size2.66%Div Yield TTM2.90%Div Yield LFY
CSPC PHARMA (01093) Income Statement
All
YOY
| (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -10.35%26.01B | -12.32%19.89B | -18.49%13.27B | -21.91%7.01B | -7.76%29.01B | -4.94%22.69B | 1.27%16.28B | 11.54%8.98B | 1.66%31.45B | 1.57%23.87B |
| Operating income | -10.35%26.01B | -12.32%19.89B | -18.49%13.27B | -21.91%7.01B | -7.76%29.01B | -4.94%22.69B | 1.27%16.28B | 11.54%8.98B | 1.66%31.45B | 1.57%23.87B |
| Cost of sales | -2.72%-8.95B | -2.11%-6.84B | 1.44%-4.56B | 7.15%-2.31B | 6.07%-8.71B | 5.26%-6.7B | 4.40%-4.63B | 1.87%-2.49B | -6.83%-9.27B | -10.29%-7.07B |
| Operating expenses | -2.72%-8.95B | -2.11%-6.84B | 1.44%-4.56B | 7.15%-2.31B | 6.07%-8.71B | 5.26%-6.7B | 4.40%-4.63B | 1.87%-2.49B | -6.83%-9.27B | -10.29%-7.07B |
| Gross profit | -15.96%17.06B | -18.37%13.05B | -25.26%8.71B | -27.56%4.71B | -8.47%20.3B | -4.80%15.99B | 3.71%11.65B | 17.70%6.5B | -0.36%22.18B | -1.70%16.79B |
| Selling expenses | 25.39%-6.46B | 27.58%-4.8B | 36.18%-3.05B | 43.90%-1.66B | 5.23%-8.66B | 5.79%-6.62B | 2.55%-4.78B | -18.97%-2.96B | 11.58%-9.14B | 13.34%-7.03B |
| Administrative expenses | 23.54%-825.46M | 29.60%-619.98M | 36.52%-401.72M | 31.37%-228.44M | 9.25%-1.08B | -2.88%-880.65M | -18.15%-632.84M | -26.51%-332.83M | -1.43%-1.19B | 2.08%-855.97M |
| Research and development expenses | -11.91%-5.81B | -7.87%-4.19B | -5.53%-2.68B | -11.37%-1.3B | -7.46%-5.19B | -5.49%-3.88B | -10.35%-2.54B | -16.04%-1.17B | -21.17%-4.83B | -25.95%-3.68B |
| Profit from asset sales | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --32.86M | ---- |
| Special items of operating profit | 171.35%938.13M | 257.35%927.55M | 233.62%575.4M | 371.54%278.47M | -17.80%345.73M | -36.05%259.57M | -19.70%172.47M | 41.09%59.06M | -48.38%420.59M | -8.36%405.88M |
| Operating profit | -14.23%4.9B | -10.00%4.37B | -18.65%3.15B | -14.35%1.79B | -23.53%5.71B | -13.72%4.86B | 4.42%3.87B | 16.13%2.09B | -1.39%7.47B | 0.27%5.63B |
| Financing cost | 11.63%-38.6M | 4.36%-31.84M | 1.47%-21.65M | -10.38%-6.74M | -68.65%-43.67M | -97.26%-33.29M | -104.95%-21.98M | -37.84%-6.11M | -4.04%-25.9M | -12.51%-16.88M |
| Share of profits of associates | 7.46%-42.5M | 17.55%-32.6M | 46.00%-14.71M | 111.85%1.78M | -11.83%-45.92M | -19.90%-39.53M | -67.65%-27.24M | -24.61%-15.01M | 3.40%-41.07M | 29.06%-32.97M |
| Share of profit from joint venture company | 77.15%-9.95M | 83.32%-6.91M | 107.94%1.94M | 162.21%8.39M | -231.67%-43.55M | -653.04%-41.44M | -983.37%-24.43M | -187.38%-13.48M | -148.43%-13.13M | -113.24%-5.5M |
| Special items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --32.86M |
| Earning before tax | -13.81%4.81B | -9.33%4.3B | -17.98%3.12B | -12.74%1.8B | -24.50%5.58B | -15.41%4.75B | 3.25%3.8B | 15.57%2.06B | -2.54%7.39B | 0.23%5.61B |
| Tax | 24.85%-931.73M | 18.74%-766.09M | 27.49%-543.62M | 29.67%-301.26M | 5.83%-1.24B | 2.28%-942.7M | -20.23%-749.66M | -37.35%-428.35M | 2.48%-1.32B | 5.98%-964.74M |
| After-tax profit from continuing operations | -10.66%3.88B | -7.00%3.54B | -15.65%2.57B | -8.29%1.49B | -28.55%4.34B | -18.13%3.8B | -0.21%3.05B | 10.94%1.63B | -2.56%6.07B | 1.62%4.65B |
| Earning after tax | -10.66%3.88B | -7.00%3.54B | -15.65%2.57B | -8.29%1.49B | -28.55%4.34B | -18.13%3.8B | -0.21%3.05B | 10.94%1.63B | -2.56%6.07B | 1.62%4.65B |
| Minority profit | -152.99%-5.72M | 1.13%25.05M | -15.74%26.2M | -1.33%16.81M | -94.59%10.79M | -83.53%24.77M | -65.85%31.09M | -57.68%17.04M | 41.74%199.37M | 45.84%150.38M |
| Profit attributable to shareholders | -10.30%3.88B | -7.06%3.51B | -15.64%2.55B | -8.36%1.48B | -26.31%4.33B | -15.94%3.78B | 1.80%3.02B | 12.88%1.61B | -3.58%5.87B | 0.60%4.49B |
| Basic earnings per share | -7.84%0.3398 | -4.09%0.3072 | -12.62%0.2229 | -5.14%0.1291 | -25.47%0.3687 | -15.35%0.3203 | 2.24%0.2551 | 13.51%0.1361 | -3.21%0.4947 | 0.93%0.3784 |
| Diluted earnings per share | -7.84%0.3398 | -4.09%0.3072 | -12.62%0.2229 | -5.14%0.1291 | -25.47%0.3687 | -15.33%0.3203 | 2.24%0.2551 | 13.51%0.1361 | -3.21%0.4947 | 0.91%0.3783 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
| Auditor | -- | -- | -- | -- | Deloitte Touche Tohmatsu Limited | -- | -- | -- | Deloitte Touche Tohmatsu Limited | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"